How does Medicare’s $50 GLP-1 bridge model affect Lilly and Novo demand?

Medicare’s new bridge model lets eligible seniors access weight loss GLP-1 drugs for $50 a month under the MFN pricing deal involving Eli Lilly and Novo Nordisk. The article says early uptake could act as a live demand signal, showing whether lower out-of-pocket costs unlock meaningful Medicare volume and support blockbuster sales expectations.